<DOC>
	<DOCNO>NCT01508117</DOCNO>
	<brief_summary>The purpose study determine whether addition investigational medication , axitinib , radiation therapy improve outcome treatment patient , age 70 .</brief_summary>
	<brief_title>Phase II Axitinib ( AG-013736 ) Elderly Glioblastoma Multiforme ( GBM ) Patients</brief_title>
	<detailed_description>The addition axitinib standard treatment experimental approve United States Food Drug Administration ( FDA ) . Axitinib work prevent new blood vessel form , tumor need make new blood vessel order grow . The study find effect , good bad , axitinib tumor . In addition , study try determine whether response axitinib overall outcome depend certain characteristic tumor .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Axitinib</mesh_term>
	<criteria>Newly diagnose patient histologically proven glioblastoma multiforme Age 70 year Karnofsky score 5080 Adequate organ function define laboratory value Life expectancy &gt; 12 week No evidence preexist uncontrolled hypertension document 2 baseline blood pressure read take least 1 hour apart . The baseline systolic blood pressure reading must 140 mm Hg , baseline diastolic blood pressure reading must 90 mm Hg . Patients whose hypertension control antihypertensive therapy eligible . Prior treatment chemotherapy radiation glioblastoma multiforme Patients extensive tumor hemorrhage Any follow within 12 month prior study drug administration : myocardial infarction , uncontrolled angina , coronary/peripheral artery bypass graft , symptomatic congestive heart failure , cerebrovascular accident transient ischemic attack 6 month deep vein thrombosis pulmonary embolism</criteria>
	<gender>All</gender>
	<minimum_age>70 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>GBM</keyword>
	<keyword>brain tumor</keyword>
</DOC>